October 14, 2022/Cancer/Radiation Oncology

Radiation Oncology-Biology Integration Network (ROBIN) Explores Precision Medicine

Multidisciplinary team to examine radiation therapy combined with immunotherapy

radiation therapy

Roughly two out of every three patients with cancer receive radiation therapy. Yet despite its widespread use, the molecular mechanisms and biology of response to radiation remains poor. The Radiation Oncology-Biology Integration Network (ROBIN) at Cleveland Clinic seeks to develop more effective radiation and immunotherapy combinations and to better understand how these approaches work for cancers of the bladder and head and neck.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In collaboration with Emory University, Cleveland Clinic researchers and clinicians will lead the studies, with the goal of developing new cancer treatment approaches by improving understanding of the drivers of efficacy. Specifically, the team will study radiotherapy in combination with antibody-drug conjugates and immune checkpoint inhibitors.

Collaboration brings together translational research and patient care

The ROBIN center will draw upon Cleveland Clinic’s high patient volumes to generate comprehensive molecular data that will provide key information to enable physicians to select the best treatment for each patient. A multidisciplinary team from the fields of radiation oncology, radiation biology and radiation physics research will bring findings in patient care back to the research lab for further examination. In addition, the creation of a cross-training workforce development program is underway to build a pipeline of scientists in radiation biology, radiation physics and clinical radiation oncology.

“The ROBIN trial will create the data needed to ultimately drive precision cancer medicine that, in the end, provides the best outcomes for each patient and helps improve quality of life,” says

Timothy Chan, MD, PhD, Chair of the Cleveland Clinic Center for Immunotherapy and Precision Immuno-Oncology.

Studying bladder cancer treatment

Omar Mian, MD, PhD, radiation oncologist at Cleveland Clinic’s Taussig Cancer Institute and researcher at the Lerner Research Institute, and Shilpa Gupta, MD, Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program, will lead one of the molecular characterization trials focusing on the combination of a targeted therapy, sacituzumab, plus radiation, for the treatment of bladder cancer. A cohort of this study also will take place at Cleveland Clinic’s Florida Research and Innovation Center, under the leadership of Anatoly Nikolaev, MD, PhD.

Understanding head and neck cancer therapies

A second clinical trial examining the effectiveness of treating recurrent head and neck cancer with radiation therapy and nivolumab, is being led by Shlomo Koyfman, MD, a radiation oncologist at the Taussig Cancer Institute.

Advertisement

Dr. Chan’s lab will analyze de-identified patient samples from both those receiving current standard of care and those in clinical trials, to generate data using multiple genetic analyses. The breadth and depth of data generated will reveal comprehensive insights into radiation-based cancer treatment strategies. In another of the funded projects in the ROBIN, Jacob Scott, MD, DPhil, radiation oncologist and head of the Theory Division in Lerner Research Institute’s Department of Translational Hematology and Oncology Research, will use artificial intelligence to decipher the temporal dynamics of all the complex changes that occur as a result of treatment.

Hear our podcast with Dr. Chan about the Radiation Oncology-Biology Integration Network.

Advertisement

Related Articles

22-CNR-3127708-CQD-Hero2-650×450-credits
November 22, 2023/Cancer/Radiation Oncology
A Germline Biomarker Offers Insight Into Treatment Selection for Men With Prostate Cancer

Correlation found between the biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

23-CNR-4164208 ASTRO 2023 graphic CQD
September 21, 2023/Cancer/Radiation Oncology
Top 10 Presentations You Don’t Want to Miss at ASTRO 2023

Highlighting top abstracts for the annual radiation oncology conference

23-CNR-3964459-CQD-Hero-650×450 SBRT
New Study Highlights Potential Benefits of Ultrasound-Guided Prostate SBRT

Transperineal ultrasound a viable, non-invasive option for monitoring intra-fractional prostate motion

ASTRO 2022 abstracts
November 4, 2022/Cancer/Radiation Oncology
Top Research from ASTRO 2022

Key abstracts highlight advances in treating locally advanced and refractory disease

21-CNR-2572058-CQD-Hero-650×450-1
March 17, 2022/Cancer/Radiation Oncology
Aggressive Daily Radiation in Breast Cancer Survivor with Angiosarcoma: A Case Study

Preoperative treatment ensures successful surgical resection

Squamous Cell carcinoma under microscopy
December 2, 2021/Cancer/Radiation Oncology
Study Identifies Prognostic Subgroups in Cutaneous Squamous Cell Carcinoma

Modification of traditional staging factors associated with survival in high-risk disease

21-CNR-2098260 CQD 650×450
November 19, 2021/Cancer/Radiation Oncology
Multimodal Therapy for Radiation-Induced Chest Wall Sarcoma: A Case Study

Hyperthermia, neoadjuvant chemoradiation and reconstruction hold promise of long-term survival

Ad